ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MedImmune, the biologics arm of AstraZeneca, has entered a three-year research collaboration with the Clinical & Translational Science Institute at the University of California, San Francisco. The pact will focus on the institute’s Catalyst Awards program, which solicits applications from university scientists who want to move their research beyond the bench. The partners say they will work together to move the most promising research projects forward. MedImmune says the collaboration should benefit its R&D as well as AstraZeneca’s small-molecule drug discovery efforts.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter